mirikizumab
Trade name: Omvoh
mAbapproved
Approved
Oct 26, 2023
Mirikizumab, sold under the brand name Omvoh, is a monoclonal antibody used for the treatment of ulcerative colitis. It is designed to attach to interleukin-23 (IL-23) and block its activity. — Wikipedia
Clinical trial activity
44 trials · 8 clinical orgs · 1 marketing orgs
Phase 1
17
Phase 2
21
Phase 3
15
Phase 4
6
Earliest trial started Oct 1, 2013 (NCT01947933)
Timeline
2010s
Indications
Approved for
Mechanism of action
- Interleukin-23 subunit alphaANTAGONIST
IL23A antagonist
- Interleukin-23INHIBITOR
Interleukin-23 inhibitor
Approval history
- approvedOct 26, 2023
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaMirikizumab ↗
- ChEMBLCHEMBL3990014 ↗
Also known as
- ly3074828
- mirikizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06997965 | Phase 4 | Feb 1, 2026 | Robarts Clinical Trials |
| NCT07292012 | Phase 4 | Jan 31, 2026 | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID), University Clermont Auvergne |
| NCT07235904 | Phase 4 | Nov 30, 2025 | Universitaetsklinikum Schleswig-Holstein |
| NCT07186101 | Phase 2 | Nov 11, 2025 | Eli Lilly |
| NCT07059130 | Phase 4 | Jul 16, 2025 | Eli Lilly, Rubix LS |
| NCT06937099 | Phase 3 | Jun 26, 2025 | Eli Lilly |
| NCT06937086 | Phase 3 | Jun 26, 2025 | Eli Lilly |
| NCT06864403 | Phase 4 | Apr 30, 2025 | Eli Lilly, University of North Carolina at Chapel Hill |
| NCT06598943 | Phase 2 | Oct 10, 2024 | Eli Lilly |
| NCT06626165 | Phase 4 | Jul 20, 2024 | Showa Inan General Hospital |
| NCT06475729 | Phase 1 | Jun 24, 2024 | Eli Lilly |
| NCT05784246 | Phase 3 | Oct 26, 2023 | Eli Lilly |
| NCT05767021 | Phase 3 | May 17, 2023 | Eli Lilly |
| NCT05509777 | Phase 3 | Dec 9, 2022 | Eli Lilly |
| NCT05644353 | Phase 1 | Dec 5, 2022 | Eli Lilly |
| NCT05515601 | Phase 1 | Aug 31, 2022 | Eli Lilly |
| NCT05069896 | Phase 1 | Oct 5, 2021 | Eli Lilly |
| NCT04844606 | Phase 3 | May 26, 2021 | Eli Lilly |
| NCT04469062 | Phase 3 | Apr 20, 2021 | Eli Lilly |
| NCT04607733 | Phase 1 | Nov 2, 2020 | Eli Lilly |
Showing 20 of 44 trials
Page 1 / 3
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 40 | 38 | 4 | 2013 |
| Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (GETAID) | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Robarts Clinical Trials | For profit | 1 | 1 | 1 | 2026 |
| Rubix LS | For profit | 1 | 1 | 1 | 2025 |
| Showa Inan General Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Universitaetsklinikum Schleswig-Holstein | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University Clermont Auvergne | Academic/Hospital | 1 | 0 | 1 | 2026 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1